FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient's continued service with the Company through the ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

Q Earnings: $3.4 billion (-17%) FY Revenues: $88.8 billion (+4%) FY Earnings: $14.1 billion (+6%) Comments: Innovative Medicin ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

Ketamine-assisted therapy lifted me out of depression. But it remains costly — and controversial Health Canada approved a ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...